InvestmentJun 17, 2026, 05:16 PM
eXoZymes Closes $5.95M Public Offering, Including Over-Allotment
AI Summary
eXoZymes Inc. announced the closing of its underwritten public offering, including the partial exercise of an over-allotment option. The offering generated gross proceeds of approximately $5.95 million before deducting underwriting discounts and expenses. The company sold a total of 330,575 units, with each unit comprising two shares of common stock and one warrant. Net proceeds are intended to support development and commercialization activities for N-trans-caffeoyltyramine ("NCT"), advance additional product opportunities, fund research and development, and for working capital and other general corporate purposes.
Key Highlights
- eXoZymes Inc. closed an underwritten public offering, generating gross proceeds of approximately $5.95 million.
- The offering included the sale of 330,575 units, with 34,440 units from the over-allotment option.
- Each unit consisted of two shares of common stock and one warrant.
- The public offering price was $8.99 per share and $0.02 per warrant.
- Warrants are exercisable at $11.24 per share, one year from issuance, and expire in five years.
- Net proceeds will support NCT development, R&D, and general corporate purposes.
Price Impact
More from EXOZ